Hybrigenics has presented the first ever clinical data from an interim analysis of a Phase II study of inecalcitol in combination with imatinib in patients with chronic myeloid leukaemia (CML). At interim, 43% of patients who had been on treatment for three months showed improvements to baseline MMR (major molecular response). Furthermore, 33% of patients who had completed one year in the study achieved a deep molecular response (DMR). Achieving and sustaining a DMR may allow patients to disc
17 Feb 2017
Encouraging initial CML clinical data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Encouraging initial CML clinical data
Hybrigenics SA Class A (ALHYG:PAR) | 0 0 0.0% | Mkt Cap: 25.2m
- Published:
17 Feb 2017 -
Author:
Juan Pedro Serrate -
Pages:
3
Hybrigenics has presented the first ever clinical data from an interim analysis of a Phase II study of inecalcitol in combination with imatinib in patients with chronic myeloid leukaemia (CML). At interim, 43% of patients who had been on treatment for three months showed improvements to baseline MMR (major molecular response). Furthermore, 33% of patients who had completed one year in the study achieved a deep molecular response (DMR). Achieving and sustaining a DMR may allow patients to disc